Clinical improvement of sepsis by extracorporeal centrifugal leukocyte apheresis in a porcine model

Lei Zhou, Dong Zhang, Ling Kong, Xiaodong Xu and Dehua Gong*

Abstract

Background: Extracorporeal blood purification therapies targeting removal of the downstream products of the inflammatory cascade in sepsis have failed to improve mortality. As an upstream process of the inflammatory cascade, activated white blood cells should be a potential therapeutic target for sepsis, and the effect of removing such cells by extracorporeal centrifugal leukocytapheresis (LCAP) is worth considering.

Methods: Fourteen peritonitis-induced septic pigs were randomly assigned to receive a sham operation (control group, n = 7) or one session of LCAP at 12 h after sepsis induction (treatment group, n = 7). Samples from peripheral blood at various time-points and from LCAP collection were tested. All pigs were euthanized at 48 h, and lung, kidney, liver and spleen tissues were obtained for histopathological examination.

Results: Two pigs died in accidents before the induction of sepsis, and 12 pigs were finally included for the statistical analysis. A significant clinical improvement was present in the treatment group relative to the control group in terms of the mean arterial blood pressure (MAP), oxygen tension (PaO2), lactic acid level, oxygenation index (PaO2/FiO2), and carbon dioxide tension (PaCO2, P < 0.05). Flow cytometry tests showed that a mixture of B cells, dendritic cells, T helper cells, cytotoxic T cells, monocytes and neutrophils were removed from the circulation by LCAP, resulting in sepsis-induced change trends in the control cells; these change trends were all flattened in the treatment group, although nonsignificantly.

Conclusions: LCAP may exert a wide-spectrum and bidirectional immunomodulatory effect on sepsis, accompanied by improvements in hemodynamics and oxygenation status.

Keywords: Sepsis, Extracorporeal centrifugal leukocytapheresis, Inflammation, Immune modulation

Introduction

Although there has been substantial progress in the management of sepsis recently, it is still a great challenge for the health care system in high-income countries, with a reported annual incidence of 31.5 million affected cases and 5.3 million deaths, which is a much higher mortality rate than that of other diseases [1, 2]. This fact facilitates perpetual efforts in exploring novel methods for the treatment of sepsis. According to the current knowledge, a dysregulated host immune response to infection is considered the key underlying pathophysiological cause for life-threatening organ dysfunction presented in sepsis. [3, 4] Therefore, methods aimed at modulating immune function have become a research approach to seeking novel treatment options for sepsis. There have been numerous investigations of the role of extracorporeal blood purification therapies in the treatment of sepsis through the removal of proinflammatory substances...
such as cytokines and endotoxins from blood (reviewed in [5]). Such therapies may be proposed as adjuncts to standard treatments (such as antibiotics, management of organ dysfunction, and surgical treatment as required). As reported, these methods include high-volume hemofiltration (HVHF) [6], cascade hemofiltration [7], hemoperfusion or plasma perfusion using endotoxins/cytokine adsorption devices such as Toraymyxin® (polymyxin B-immobilized fiber column), [8] CytoSorb® [9], the AN69ST membrane [10], and oXiris® [11]. However, the effectiveness of these methods remains controversial, with most trials failing to prove their superiority over standard treatments [5]. The failure of methods targeting the removal of plasma toxic solutes should turn research interests to targeted intervention of immune cells, which are the major sources of cytokine production. Sepsis induces immune alterations in innate and adaptive cells [3], and marked elevation of white blood cells (WBCs) in circulation is a physical response to infection in the early stage of sepsis. Based on these considerations, it is worth investigating the effect of eliminating dysfunctional WBCs from the circulation during the early stage of sepsis using centrifugal cell separation techniques such as leukocytapheresis (LCAP). To address this issue, we performed a randomized controlled experimental study to explore the effect of LCAP on immune modulation and improvement of clinical conditions in a peritonitis-induced septic porcine model.

Methods
All animal experiments were performed in the Department of Comparative Medicine, Jinling Hospital, with a protocol previously approved by the Institutional Animal Care and Use Committee of Jinling Hospital, Nanjing University (grant number 2017NZGKJ-019). The treatments of animals were fully in compliance with the National Research Council’s 1996 Guide for the Care and Use of Laboratory Animals [12].

Animal preparation
Fourteen domestic healthy sex-unspecified pigs with weights of 50–60 kg were fed in the Department of Comparative Medicine 1 week prior to the study and were fasted except for free access to water for 8 h just before the study. At the start of the study, the pigs were anesthetized by intramuscular injection with a mixture of midazolam (2 mg/kg), atropine (1.0 mg) and diazepam (20 mg), followed by a continuous infusion of 2% propofol (4 mg/kg/h) through the ear vein as maintenance anesthesia. Thereafter, the pigs received an intraperitoneal injection of a suspended solution obtained by incubation of previously collected autologous feces (1.0 g/kg) with 200 ml sterile saline at room temperature (25–30 °C) for 8 h. In the following 12 h, the pigs were transferred to the animal intensive care unit without constraints, and those with an increase of ≥2 sequential organ failure assessment (SOFA) points, which included assessment of respiratory, hematological, circulatory, nervous, digestive and urinary systems [4, 13], were considered successful in the induction of sepsis. Then, the pigs were anesthetized again. Tracheal intubation with no mechanical ventilation was performed to keep the airways open. Basal fluid support (7 ml/kg/h) was given using the hospital-made balanced solution (Na+ 142.5 mmol/L, K+ 3.72 mmol/L, Ca2+ 1.5 mmol/L, Mg2+ 1.56 mmol/L and glucose 11.0 mmol/L, HCO3− 34 mmol/L) (Patent Number: CN1338316A) [14–16]. Vasopressors (such as norepinephrine and dopamine) and fluid resuscitation were used to stabilize the arterial pressure if necessary. A dual-lumen catheter (12F 12.5 cm, BARD, U.S. A) was inserted into the right jugular vein for vascular access.

After the induction of sepsis, all the pigs were randomly assigned to the control group and the treatment group at a ratio of 1:1. The control group received only fluid infusion and vasopressors if necessary, while the treatment group received one session of extracorporeal centrifugal LCAP in addition to the therapies given in the control group.

Extracorporeal centrifugal leukocytapheresis therapy
In the treatment group, LCAP started 12 h after intraperitoneal injection of the feces-suspended solution. The LCAP procedures followed the instructions of the “MNC” program provided by the manufacturer of the Cobe Spectra Apheresis System (CaridianBCT, Collins Avenue, Lakewood, Colorado 80215, U.S.A.). This program mainly harvests peripheral mononuclear cells from the circulation through a centrifugal cell separation technique. The blood flow rate was set at 40–60 ml/min, with anticoagulation by infusion of acid citrate dextrose solution A (ACD-A) at a blood flow rate ratio of 1:10–1:15 (Fig. 1A). The rate of the cell harvesting pump was set at 1 ml/min, with adjustment based on the color of the harvesting fluid according to a colorimetric card provided by the manufacturer (Fig. 1B). Each session lasted 1–1.5 h, with two times the total blood volume (TBV) processed.

Monitoring and sampling
All pigs were euthanized by injection 42 h after induction of sepsis. Vital signs were monitored throughout the whole period of the experiment. Data and blood sampling were collected at baseline, 12 h after induction of sepsis, 42 h after induction of sepsis in all pigs, and after LCAP in the treatment group (Fig. 1C). Samples from the
harvested product were also collected for further measurements. Blood cell analysis, indices of hepatic and renal function, arterial blood gas analysis and endotoxin levels were tested in the Clinical Laboratory of Jinling Hospital. Endotoxin levels were tested by a tachypleus amoebocyte lysate assay. C-creative protein (CRP), procalcitonin (PCT), and cytokines (IFN-γ, TNF-α, IL-6, IL-10) were tested by a ELISA kit (Elabscience Biotechnology Co., Wuhan, China) following the manufacturer’s instructions. Myeloperoxidase (MPO) activity was measured by the method described by S Fietz et al. [17].

Cell typing was performed via flow cytometry using various leukocyte surfaces, as follows: monocytes by CD14 (Abcam, ab186689) and CD163 (AbD Serotec, MCA2311F), B cells by CD21 (Abcam, ab65809), dendritic cells by CD3−CD172a+ (AbD Serotec, MCA1222A647 and MCA2312F), T helper (Th) cells by CD3+CD4+ (AbD Serotec, MCA1222A647 and MCA1749F), cytotoxic T (Tc) cells by CD3+CD8+ (AbD Serotec, MCA1222A647 and Abcam, ab25536), and activated neutrophils by CD113R (AbD Serotec, MCA2309F).

**Histopathology**
At the end of the experiment, the pigs were euthanized through rapid intravenous injection of propofol until respiratory and cardiac arrest. Lung, kidney, liver and spleen specimens obtained after euthanasia were fixed with 10% formalin for histopathological examination. Hematoxylin–eosin staining was performed routinely, and immunohistochemistry was also performed using antibodies specific for anti-CD11b [EPR1344] (Abcam, ab133357) and SIRPA/CD172a (clone BL1H7) (LifeSpan, LS-C187488). Relative gray values of positive tissues were calculated. Two independent pathology professionals blindly evaluated and scored the severity of the lesions as follows: 0, normal; 0.5, slight or very small lesions; 1, mild or small lesions; 2, moderate or common lesions; 3, severe or diffusive lesions; and 4, extremely severe or massive lesions [18].
Calculations

Females : \( \text{TBV in ml} = 183 + \left[356 \times \text{height}^3 (\text{m})\right] + \left[33.1 \times \text{weight (kg)}\right] \)

Males : \( \text{TBV in ml} = 604 + \left[367 \times \text{height}^3 (\text{m})\right] + \left[32.2 \times \text{weight (kg)}\right] \)

Total leukocyte count = leukocyte concentration \( \times 10^9 / \text{L} \times \text{TBV (mL/1000) } \)

Total collected leukocyte count = collected leukocyte concentration \( \times 10^9 / \text{L} \times \text{collection volume (mL/1000) } \)

Statistical analysis

Means ± standard deviations are presented for normally distributed continuous variables, and medians (inter-quartile ranges) are presented for skewed continuous variables. The Shapiro–Wilk test was used to assess the normality of the variables. The independent-samples T test was used to compare normally distributed parameters, and a nonparametric test was used to compare skewed parameters of the control group and treatment group. The differences in normally distributed parameters among time points (≥ 3 time points) in each group were compared by one-way ANOVA, and the least significant difference (LSD) test was used for the post hoc test. The differences in skewed parameters among time points (≥ 3 time points) in each group were compared by nonparametric tests and post hoc tests for multiple comparisons. Data analyses were performed by SPSS 21.0 software, and graphs were processed by GraphPad Prism 6 software. Statistical significance was set at P < 0.05.

Results

Two pigs died before the induction of sepsis, one because of a catheterization-associated accident and one because of an intubation-associated accident. Finally, 12 pigs were randomized equally into the control and treatment groups. All of them reached the criteria of sepsis [2] 12 h after induction, with blood LPS positivity, and survived to the end of the study, except one pig in the treatment group, which experienced resistant hypotension during LCAP and died 8 h after the end of treatment, with data included in the final analysis.

| Table 1 Baseline variables between control and treatment groups* |
|---------------------------------------------------------------|
| Control group | Treatment group | P value |
|----------------|----------------|---------|
| Weight (kg)    | 54.4 ± 8.7     | 54.3 ± 11.3 | 0.995 |
| Body length (cm)| 125.5 (124.0, 128.5)| 125.0 (124.0, 132.3) | 0.937 |
| TBV (L)         | 2.8 ± 0.5      | 2.8 ± 0.5 | 1     |
| MAP (mmHg)      | 125.6 ± 10.1   | 130.5 ± 13.5 | 0.932 |
| HR (beats/minute) | 103 ± 11.1    | 105 ± 8.6 | 0.438 |
| Blood cells    |                |          |
| Leukocyte (× 10^9/L) | 15.6 ± 1.5 | 14.2 ± 3.1 | 0.394 |
| Hemoglobin (g/L) | 104.0 ± 13.2 | 99.7 ± 12.4 | 0.611 |
| Hct (%)         | 30.8 ± 4.4     | 33.6 ± 3.9 | 0.327 |
| Platelet (× 10^9/L) | 365.75 ± 107.0 | 367.5 ± 138.0 | 0.984 |
| B Cell (%)      | 3.6 ± 1.1      | 3.5 ± 1.5 | 0.947 |
| DC Cell (%)     | 4.2 ± 1.5      | 4.2 ± 1.5 | 0.997 |
| Th cell (%)     | 4.0 ± 2.7      | 6.9 ± 4.2 | 0.271 |
| Tc cell (%)     | 7.5 ± 1.5      | 13.1 ± 5.6 | 0.093 |
| Th/Tc cells (%) | 51.9 ± 25.5    | 56.9 ± 36.8 | 0.822 |
| Monocyte (%)    | 1.9 (1.6, 2.4) | 2.3 (1.8, 4.2) | 0.310 |
| Neutrophil (%)  | 48.6 ± 3.8     | 42.6 ± 8.1 | 0.210 |
| Hepatic and renal function |       |          |
| ALT (U/L)      | 82.0 ± 64.2    | 105.0 ± 78.4 | 0.640 |
| AST (U/L)      | 33.5 (28.0, 64.5) | 365 (31.8, 60.5) | 0.485 |
| TBIL (μmol/L)  | 1.9 ± 1.1      | 1.5 ± 1.0 | 0.531 |
| DBIL (μmol/L)  | 0.4 ± 0.2      | 0.3 ± 0.3 | 0.629 |
| IBIL (μmol/L)  | 1.5 ± 1.0      | 1.2 ± 0.8 | 0.562 |
| Alb (g/L)      | 23.3 ± 63      | 240 ± 2.7 | 0.807 |
| Creatine (μmol/L) | 94.5 ± 19.2 | 91.5 ± 20.9 | 0.825 |
| Urea (mmol/L)  | 3.1 ± 1.0      | 2.6 ± 0.6 | 0.359 |
| Blood gas assay|                |          |
| PH             | 7.5 ± 0.04     | 7.5 ± 0.02 | 0.543 |
| PaO2 (mmHg)    | 99.0 (94.8, 113.3) | 96.0 (86.5, 101.5) | 0.310 |
| PaCO2 (mmHg)   | 47.0 ± 4.2     | 46.8 ± 3.8 | 0.949 |
| PICO2/FICO2 (mmHg) | 521.6 ± 83.3 | 447.6 ± 42.6 | 0.098 |
| Lac (mmol/L)   | 1.6 ± 0.7      | 1.6 ± 0.2 | 0.868 |

Both the control and treatment group were induced sepsis after baseline evaluation

TBV total blood volume, MAP mean arterial blood pressure, HR heart rate, Hct hematocrit, DC cell dendritic cell, Th cell T helper cell, Tc cell cytotoxic T cell, ALT alanine transaminase, AST aspartate aminotransferase, TBIL total bilirubin, DBIL direct bilirubin, IBIL indirect bilirubin, Alb albumin, PaO2 partial pressure of arterial oxygen, PaCO2 partial pressure of arterial carbon dioxide, SaO2 oxyhemoglobin saturation, Lac lactate

There were no significant differences in any measured data between the control group and treatment group at baseline (Table 1).

Clinical and histology findings

The systemic hemodynamics and oxygenation status are summarized in Table 2. In contrast to the control group, improvements in clinical conditions were found in the
intervention groups, manifesting as significantly a higher MAP, PaO₂, and PaO₂/FiO₂ and a lower heart rate, lactic acid level and PCO₂ (P < 0.05). These results indicate that LCAP therapy improved alveolar ventilation and maintained hemodynamic stability. The liver and kidney functions did not change significantly in either group (data not shown).

Histological examination showed no significant difference in the degree of organ lesions between the two groups (2.5 ± 1.32 vs. 3.4 ± 2.7, P > 0.05) or the lesion scores of each organ, but more severe lesions of the lung (2.0 ± 1.4 vs. 0.0 ± 0.0) and spleen (0.6 ± 0.9 vs. 1.4 ± 0.8) were found in the control group compared with the intervention group (Fig. 2A). In the control group, there were more lymphoid follicles around the bronchus of the lung, and more congestion in the splenic red pulp was detected. (Fig. 2D). CD172⁺ cell infiltration was more common in the kidneys (0.38 ± 0.05 vs. 0.31 ± 0.05, P = 0.049) but less common in the lungs (0.32 ± 0.03 vs. 0.39 ± 0.01, P = 0.016) of the intervention group compared to the control group (Fig. 2B, E). CD11b⁺ cell infiltration was not significantly different in any tissue between the groups (Fig. 2C).

Changes in inflammatory cytokines
The changes in plasma cytokine levels are shown in Fig. 3. After treatment, the levels of PCT, TNF-α, INF-γ and IL-6 were not different between the two groups; the CRP level and MPO activity of the treatment group were higher than those of the control group (P < 0.05), and IL-10 was lower in the treatment group, but the difference was not significant.

Composition of the collections of LCAP and changes in peripheral blood cells
The average volume of collections was 184 ± 120.7 ml. The leukocyte, RBC and platelet counts in the collection were 79.6%, 1.2%, and 41.1% of the pretreatment levels of

### Table 2 Parameters of systemic hemodynamics and oxygenation state between control and treatment groups*

|                         | Baseline | 12 h    | 18 h    | 42 h    | P' value |
|-------------------------|----------|---------|---------|---------|----------|
| **MAP (mmHg)**          |          |         |         |         |          |
| Control                 | 125.6 ± 10.1b | 110.3 ± 17.6 | 93.2 ± 11.3 | 85.3 ± 16.3 | 0.015    |
| Treatment               | 130.5 ± 13.5a | 101.2 ± 13.7c | 99.2 ± 20.5 | 110.3 ± 9.5 | 0.049    |
| P value                 | 0.932 | 0.297 | 0.053 | 0.031 | –        |
| HR (beats/minute)       |          |         |         |         |          |
| Control                 | 103 ± 11.1b | 112.6 ± 14.5 | 109.7 ± 20.3 | 130.6 ± 15.6 | 0.001    |
| Treatment               | 105 ± 8.6d | 120.1 ± 6.2d | 123.5 ± 12.5 | 100.3 ± 23.7 | 0.049    |
| P value                 | 0.438 | 0.683 | 0.044 | 0.015 | –        |
| **PH**                  |          |         |         |         |          |
| Control                 | 7.5 ± 0.04 | 7.6 ± 0.04 | –       | 7.5 ± 0.03 | 0.064    |
| Treatment               | 7.5 ± 0.02 | 7.5 ± 0.08 | 7.5 ± 0.03 | 7.5 ± 0.03 | 0.138    |
| P value                 | 0.543 | 0.021 | –     | 0.551 | –        |
| **PaO₂ (mmHg)**         |          |         |         |         |          |
| Control                 | 99.0 (94.8, 113.3)b | 87.0 (77.5, 94.0) | –       | 74.0 (69.5, 78.3) | 0.025    |
| Treatment               | 96.0 (86.5, 101.5)a | 75.5 (64.8, 82.8)c | 77.5 (72.3, 83.8) | 95.5 (92.3, 96.3) | 0.011    |
| P value                 | 0.310 | 0.092 | –     | 0.003 | –        |
| **PaO₂/FiO₂**           |          |         |         |         |          |
| Control                 | 521.4 ± 83.3ab | 390.3 ± 38.7 | –       | 352.3 ± 20.9 | 0.000    |
| Treatment               | 447.6 ± 42.4a | 381.3 ± 50.7c | 369.1 ± 39.6 | 450 ± 12.3 | 0.003    |
| P value                 | 0.098 | 0.779 | –     | 0.000 | –        |
| **PaCO₂ (mmHg)**        |          |         |         |         |          |
| Control                 | 47.0 ± 4.2a | 45.0 ± 1.4c | –       | 48.2 ± 1.7 | 0.049    |
| Treatment               | 46.8 ± 3.8b | 46.3 ± 6.2 | 46.0 ± 2.4 | 41.5 ± 2.1 | 0.003    |
| P value                 | 0.949 | 0.051 | –     | 0.001 | –        |
| **Lac (mmol/L)**        |          |         |         |         |          |
| Control                 | 1.6 ± 0.7ab | 2.9 ± 0.5 | –       | 3.1 ± 1.3 | 0.034    |
| Treatment               | 1.6 ± 0.2a | 3.3 ± 1.5c | 1.4 ± 0.4 | 1.2 ± 0.3 | 0.003    |
| P value                 | 0.868 | 0.112 | –     | 0.008 | –        |

*Both the control and treatment group were induced sepsis after baseline evaluation

MAP mean arterial blood pressure, HR heart rate, PH pondus hyrogenil, PaO₂ partial pressure of arterial oxygen, PaCO₂ partial pressure of arterial carbon dioxide, Lac lactate

P < 0.05 stands for statistical significance between control and treatment groups

P' < 0.05 stands for statistical significance within every time points at each group

a stands for statistical significance between baseline and 12 h

b stands for statistical significance between baseline and 42 h

c statistical significance between 12 and 42 h through post hoc test
blood, respectively (Fig. 4A). For leukocyte subgroups, the counts of Tc cells, B cells, DC cells and Th cells in the collection were 250%, 150%, 150%, and 6.9% of the pre-treatment levels of blood, respectively. The constituent proportions in the collected leukocytes were as follows: B cells 3.62%, Th cells 5.90%, Tc cells 7.14%, DC cells 8.78%, monocytes 8.18%, and activated neutrophils 58.24% (Fig. 4B).

After the induction of sepsis, the pigs in the control group presented with a progressive increase in leukocyte count, a decrease in platelet count and a slight decrease in hemoglobin level, while in the intervention group, the leukocyte count declined post-LCAP and returned to the baseline level after 24 h, accompanied by a significant decrease in hemoglobin level and platelet count (Fig. 4C, D and E). However, there was no statistically significant difference between the two groups.

Changes in subgroups of leukocytes
After the induction of sepsis, with a progressive increase in leukocyte count, the subgroups of leukocytes presented divergent patterns: in the control group, the counts of DCs, monocytes and neutrophils increased, while the counts of Th cells declined; in the treatment group, the change trends were obviously flattened (Fig. 5). The numbers of B cells, Tc cells, DC cells, monocytes and activated neutrophils were lower and that of Th cells was higher in the treatment group than in the control group at 24 h post-treatment, although nonsignificantly. The ratios of Th cells and Tc cells (Th/Tc) were significantly higher in the treatment group than in the control group (P = 0.015) (Fig. 5E).

The treatment had different effects on subgroups of leukocytes: no change was found for B cells, Th cells, or Tc cells, but a significant reduction of DC cells and neutrophils occurred with treatment. After treatment, DC cells and monocytes rebounded after 24 h (P < 0.05) (Fig. 5H).

Discussion
This preliminary study demonstrated that extracorporeal cellular apheresis therapy yields an immunomodulatory effect accompanied by clinical improvement of systemic hemodynamics and oxygenation status in a
Fig. 3 Changes in inflammatory cytokines. 

**A** PCT; **B** CRP; **C** TNF-α; **D** INF-γ; **E** IL-10; **F** IL-6; **G** MPO. The (*) stands for statistical significance between the two groups (P < 0.05). Abbreviations: PCT, procalcitonin; CRP, C reaction protein; MPO, myeloperoxidase. (Induction, baseline and sepsis induction; Pre-Tr, 12 h after sepsis induction and before treatment; Post-Tr, the end of treatment; End, 24 h after treatment and time before euthanasia)
peritonitis-induced septic porcine model, which to our knowledge is the first study to use the extracorporeal centrifugation technique in sepsis therapy.

In this study, we established a sepsis model in domestic pigs by intraperitoneal injection of a suspended solution containing previously incubated autologous feces (1.0 g/kg). This model has an identical size, endotoxin sensitivity, tissue antigenicity and immune response as that in human beings and is suitable for investigating the effect of extracorporeal blood therapy in animal models [19]. Unlike other models using a single infusion of specific live bacteria [20, 21] or endotoxin [22] to induce a transient reaction other than a sustained process, we used a peritonitis-induced sepsis model to mimic polymicrobial and progressive characteristics of clinical situations, most importantly, with an appropriate sepsis severity to avoid rapid death within the first 6 to 12 h due to an overly serious condition [23, 24] and to guarantee a sufficient survival time for the completion of the study. As reported in some experiments, an observed time that is too short may not be enough to obtain a full view of sepsis at the end of the investigation [25, 26]. Notably, we administered the intervention 12 h after the induction of sepsis, which more closely conforms to the clinical real world, rather than before or immediately after the induction of sepsis, as reported in some studies [21, 25]. Since time is needed for the treatment to produce the therapeutic effect, we also spared a 24 h time window to observe the effect of the treatment.

Organ dysfunction is the clinical feature of sepsis, involving hypotension, acute respiratory distress syndrome, disseminated intravascular coagulation and so on [27], and the cumulative effect of organ dysfunction is the strongest predictor of mortality [28]. We observed that after 12 h of sepsis induction, animals showed a decrease in PaO2 and PaO2/FiO2 and an increase in lactate levels, and the trend was further obvious if not treated, which indicated lung injury. After 18 h of sepsis induction,
blood pressure showed a downward trend, which is an indication of circulatory disorders. At the 12 h time point, there was a significant difference in the pH value between the control and treatment groups; however, in view of clinical practice, the pH difference of 0.1 units had no clinical significance, and the model of the two groups was consistent. Organ dysfunction is a complicated pathophysiologic process and is a result of the joint
action of multiple responses to inflammation, one of which is immune dysregulation [29].

Immune dysfunction of both the native and adaptive immune systems is thought to be the essence of the pathophysiology of sepsis [3]. In the traditional view, sepsis is a process that shifts from initial proinflammatory reactions to subsequent anti-inflammatory reactions, manifested as an initial significant increase in peripheral blood leukocytes, especially neutrophils and monocytes, immediately following lymphopenia [30]. However, in this study, we observed a significant increase in neutrophils and monocytes and a decrease in lymphocytes (including B cells, Th cells and Tc cells) in the initial 12 h of sepsis, although without a significant difference. As in the profile of serum cytokines, a simultaneous proinflammatory and anti-inflammatory response was present. This conforms to the characteristics of the immune response in sepsis recently described by Xiao WZ et al. [31], in which they revealed a simultaneous rapid and sustained upregulation of genes involved in the innate immune and pro/anti-inflammatory response, as well as a downregulation of genes involved in adaptive immunity in patients suffering from severe trauma or burn injury.

Leukocytapheresis is a technique using extracorporeal centrifugation to separate blood constituents according to their density, and we used the MNC program in this study to remove blood MNCs from the circulation, with the expectation of attenuating the negative reactions of sepsis. As revealed by the results, various kinds of blood-formed elements were removed by LCAP, including B cells, CD4+ T cells, CD8+ T cells, DC cells, monocytes, platelets, and neutrophils, all of which are involved in sepsis-induced innate and adaptive immune derangements relevant to sepsis recovery and survival [3]. The cell selectivity (different cells were cleared in different amounts and ratios) may have been related to the cell density because LCAP stratified the blood components by centrifugal force according to the specific gravity of different cells. The effects of LCAP on sepsis as revealed by the study should be a wide-spectrum and bidirectional effect on sepsis-activated immune cells, manifested as a flattening of the change trends of various immune cells induced by sepsis, accompanied by improvement of two vital clinical conditions of sepsis, that is, hemodynamics and oxygenation.

An interesting phenomenon shown in our experiment is that a considerable quantity of neutrophils was removed by LCAP via the MCN program because the density difference between granulocytes and mononuclear cells will generally make them appear in different layers under density gradient centrifugation. This may be explained by the fact that abnormally dense neutrophils, also called low-density neutrophils (LDNs), may be present in the blood of patients with infections, cancer, pregnancy and autoimmune diseases [32]. However, thus far, it is difficult to distinguish LDNs from normal-density neutrophils (NDNs) by common markers such as CD11b, CD15, CD66b and CD33, although a difference in the expression level may exist [33]. We used CD11b as a marker [34] to show activated neutrophils accounting for 59.6% of the collection solution by LCAP and a lower level of them in circulation after LCAP, but with a significantly higher level of MPO, an indicator of the antimicrobial activity of neutrophils [35]. This result may imply that elimination of overactivated neutrophils from the circulation does not impair but rather enhances the antimicrobial capacity of the body. Another interesting phenomenon is that all the cells rebounded after 24 h of treatment, although only the rebounding of DC cells and monocytes was statistically significant. The apoptosis of DC cells engages in the immune suppression of sepsis [36]. Multiple reports have shown that prevention of sepsis-induced DC apoptosis or augmentation of DC function enhances sepsis survival [37, 38]. The long-term effect (at least 24 h) of LCAP increases the number of DC cells, and cell function needs to be explored in the future.

Other methods have also been reported for the extracorporeal removal of activated immune cells. One of them is a selective cytopheretic device (SCD) with regional citrate anticoagulation, which was reported to absorb activated leukocytes (mainly neutrophils) and improve the 60-day mortality when the postfilter ionized calcium (iCa) level was ≤0.4 mmol/L [39]. Cell-sorba is a device with polyethyleneptarate fibers that unselectively capture monocytes, granulocytes, and lymphocytes and is used for the treatment of inflammatory bowel disease in Japan and Europe, but its effects remain unclear [40]. These are all complicated extracorporeal circulation techniques, requiring a high dose of anticoagulants, central venous catheterization to afford a high blood flow rate, and a specialized team to handle the complex circuits, which obviously hinder their clinical applications regardless of the clinical effects. In contrast, extracorporeal centrifugal cellular apheresis, as a mature technique with low blood flow rates of 40–60 ml/min, a simple filter-free circuit and low clotting risk, may be worth further exploring for its application in the treatment of sepsis.

The obvious limitations of our study should be stated. First, the sepsis model of the study was not very severe, with modest pathological lesions in organs and a survival time beyond 48 h in order to guarantee the accomplishment of the study. Second, no antibiotics, as recommended by consensus [2], were used for the treatment of sepsis; third, only one treatment at a
specific time point of sepsis was administered in the study, considering that sepsis is a sustained inflammatory response process, and one shot is obviously not enough. Finally, no hard endpoints were considered in the study, and consequently, further studies are needed to investigate the effect of LCAP on sepsis mortality.

Conclusions
In conclusion, this preliminary study using LCAP to treat septic pigs revealed an immunomodulatory effect with improvement of vital clinical conditions. However, further studies are still needed to verify its role in improving the mortality of sepsis.

Abbreviations
LCAP: Leukocytapheresis; MAP: Mean arterial blood pressure; HVHF: High-volume hemofiltration; WBC: White blood cells; ACD-A: Acid citrate dextrose solution A; TBV: Total blood volume; CRP: C-reactive protein; PCT: Procalcitonin; MPO: Myeloperoxidase; LDN: Low-density neutrophils; NDNs: Normal density neutrophils; SCD: Selective cytopheretic device; iCa: Ionized calcium.

Acknowledgements
The authors would like to thank Breeder Zhang and Mr. Zhao at the Department of Comparative Medicine, Jinling Hospital.

Author contributions
LZ performed the experiments, analyzed the data and wrote the manuscript. DZ and LK assisted in performing the experiments. XDX helped to perform the flow cytometry. DHG provided ideas, guided the experiments and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the Natural Science Foundation of China (Grant Number 81470992) and the National Key R&D Program of China (Grant Number 2017YFC1104404). The funding sources were not involved in the design of the study, in the collection, analysis and interpretation of data, in the writing of the report; or in the decision to submit the paper for publication. The corresponding author had access to all data in the study and had final responsibility for the decision to submit the paper for publication.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
All animal experiments were performed in the Department of Comparative Medicine, Jinling Hospital, with a protocol previously approved by the Institutional Animal Care and Use Committee of Jinling Hospital, Nanjing University (Grant Number 2017NZGKJ-019).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 1 August 2022 Accepted: 4 November 2022 Published online: 22 November 2022

References
1. Fleischmann C, Scheraa A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K. International Forum of Acute Care T. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193:259–72.
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2016. Intensive Care Med. 2017;43:304–77.
3. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126:23–31.
4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
5. Monard C, Rimmelte T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47(Suppl 3):1–14.
6. Quentet JP, Sirquet C, Vinsonneau C, Barbar SD, Vinault S, Deckert V, Lemaire S, Hassain AA, Bruyere R, Souweine B, et al. Very high volume hemofiltration with the Cascade system in septic shock patients. Intensive Care Med. 2015;41:2111–20.
7. Payen D. Haemoperfusion with polymyxin B membrane: recent results for an old debate! Anaesth Crit Care Pain Med. 2019;38:3–4.
8. Payen D. Haemoperfusion with polymyxin B membrane: recent results for an old debate! Anaesth Crit Care Pain Med. 2019;38:3–4.
9. Schadler D, Pausch C, Heise D, Meier-Hellmann A, Bredelau J, Weiler N, Marx G, Putensen C, Spies C, Jorres A, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE. 2017;12:e0187015.
10. Yamamoto M, Yoshida O, Moriyama K, Shimomura Y, Nakamura T, Kuriyama N, Hara Y, Yamada S. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial. 2011;15:385–93.
11. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2015;3:6.
12. NRC (National Research Council). Guide for the care and use of laboratory animals, 7th edn. Washington DC: National Academy Press. 1996.
13. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score—development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23:374.
14. Wu B, Zhang K, Xu B, Ji D, Liu Z, Gong D. Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purif. 2015;39:306–12.
15. Wu B, Gong D, Xu B, He Q, Liu Z, Ji D. Decreased platelet count in severe tetramine poisoning. Blood Purif. 2006;24:524–30.
16. Dehaua G, Daxi J, Hongxiong X, Bin X, Yun L, Leishi L. Sequential hemoperfusion and continuous venovenous hemofiltration in treatment of severe tetramine poisoning. Blood Purif. 2006;24:524–30.
17. Feitz S, Bondzio A, Moschos A, Hertsch B, Emspanier R. Measurement of equine myeloperoxidase (MPO) activity in synovial fluid by a modified MPO assay and evaluation of joint diseases - an initial case study. Res Vet Sci. 2008;84:347–53.
18. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224–32.
19. Goldfarb RD, Dellinger RP, Parrillo JE. Porcine models of severe sepsis: emphasis on porcine peritonitis. Shock. 2005;24(Suppl 1):75–81.
20. Molnar L, Nemeth N, Berhes M, Hajdu E, Papp L, Molnar A, Szabo J, Deak A, Fulesdi B. Assessment of cerebral circulation in a porcine model of intravenously given E. coli induced fulminant sepsis. BMC Anesthesiol. 2017;17:98.
21. Sauer M, Altrichter J, Mencke T, Klohr S, Thomsen M, Kreuzter HJ, Noldge-Schomburg G, Mitzner SR. Role of different replacement fluids during extracorporeal treatment in a pig model of sepsis. Ther Apher Dial. 2013;17:84–92.
22. Lipcsey M, Larsson A, Eriksson MB, Sjolín J. Effect of the administration rate on the biological responses to a fixed dose of endotoxin in the anesthetized pig. Shock. 2008;29:173–80.

23. Ding F, Song JH, Jung JY, Lou L, Wang M, Charles L, Westover A, Smith PL, Pino CJ, Buffington DA, Humes HO. A biomimetic membrane device that modulates the excessive inflammatory response to sepsis. PLoS ONE. 2011;6:e18584.

24. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock. 2008;30(Suppl 1):S3–9.

25. Blielevens C, Grottke Q, Groening S, Horneck M, Kopp R, Singh S, Arens J, Rossaint R. Septic porcine blood does not further activate coagulation during in vitro membrane oxygenation. Eur J Cardiothorac Surg. 2017;51:449–56.

26. Park I, Lee JH, Jang DH, Kim D, Chang H, Kwun H, Kim S, Kim TS, Jo YH. Characterization of fecal peritonitis-induced sepsis in a porcine model. J Surg Res. 2019;244:492–501.

27. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.

28. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5:4–11.

29. Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin. 2018;34:63–80.

30. Martin MD, Badovinac VP, Badovinac GP, Griffith TS. CD4 T cell responses and the sepsis-induced immunoparalysis state. Front Immunol. 2020;11:1364.

31. Basu PP, Shah NJ, Krishnaswamy N, Pacana T. Prevalence of restless legs syndrome in patients with irritable bowel syndrome. World J Gastroenterol. 2011;17:4404–7.

32. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil diversity in health and disease. Trends Immunol. 2019;40:565–83.

33. Tay SH, Celhar T, Fairhurst AM. Low-density neutrophils in systemic lupus erythematosus. Arthritis Rheumatol. 2020;72:1587–95.

34. Simms HH, D’Amico R. Lipopolysaccharide induces intracytoplasmic migration of the polymorphonuclear leukocyte CD11b/CD18 receptor. Shock. 1995;3:196–203.

35. Kothari N, Keshari RS, Bogra J, Kohli M, Abbas H, Malik A, Dikshit M, Barthwal MK. Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J Crit Care. 2011;26(435):e431-437.

36. Pastille E, Didovic S, Brauckmann D, Rani M, Agrawal H, Schade F, Zhang Y, Flohe SB. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J Immunol. 2011;186:977–86.

37. Efiron PA, Martins A, Minnich D, Tinsley K, Ungaro R, Bahjat FR, Hotchkiss R, Clare-Salzler M, Moldawer LL. Characterization of the systemic loss of dendritic cells in murine lymph nodes during polymicrobial sepsis. J Immunol. 2004;173:3035–43.

38. Scumpia PO, McAuliffe PF, O’Malley KA, Ungaro R, Uchida T, Matsumoto T, Remick DG, Clare-Salzler MJ, Moldawer LL, Efiron PA. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J Immunol. 2005;175:3282–6.

39. Tumlin JA, Galphin CM, Tolwani AJ, Chan MR, Vijayan A, Finkel K, Szamosfalvi B, Dev D, DaSilva JR, Astor BC, et al. A multi-center, randomized, controlled, pivotal study to assess the safety and efficacy of a selective cytopheretic device in patients with acute kidney injury. PLoS ONE. 2015;10:e0132482.

40. Mitsuyama K, Yamasaki H, Kuwaki K, Takeuchi T, Saga H, Suto M. Recent understanding of leukocytapheresis (LCAF) for the treatment of inflammatory bowel disease. Curr Pharm Des. 2009;15:2110–9.